Janux Therapeutics, Inc. (JANX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -143.56M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 123.98M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-143.56M | (m) | (m) | $123.98M | (m) | (m) |
| 2026-03-31 | $-156.98M | (m) | (m) | $127.65M | (m) | (m) |
| 2025-12-31 | $-157.67M | (m) | (m) | $125.90M | (m) | (m) |
| 2025-09-30 | $-144.29M | (m) | (m) | $115.15M | (m) | (m) |
| 2025-06-30 | $-144.88M | (m) | (m) | $99.14M | (m) | (m) |
| 2025-03-31 | $-113.58M | (m) | (m) | $79.37M | (m) | (m) |
| 2024-12-31 | $-98.85M | (m) | (m) | $68.39M | (m) | (m) |
| 2024-09-30 | $-85.96M | (m) | (m) | $59.82M | (m) | (m) |
| 2024-06-30 | $-65.93M | (m) | (m) | $53.10M | (m) | (m) |
| 2024-03-31 | $-72.86M | (m) | (m) | $53.13M | (m) | (m) |
| 2023-12-31 | $-72.98M | (m) | (m) | $54.92M | (m) | (m) |
| 2023-09-30 | $-75.11M | (m) | (m) | $58.12M | (m) | (m) |
| 2023-06-30 | $-77.32M | (m) | (m) | $59.96M | (m) | (m) |
| 2023-03-31 | $-73.83M | (m) | (m) | $59.12M | (m) | (m) |
| 2022-12-31 | $-67.09M | (m) | (m) | $53.44M | (m) | (m) |
| 2022-09-30 | $-62.31M | (m) | (m) | $49.18M | (m) | (m) |
| 2022-06-30 | $-55.20M | (m) | (m) | $43.84M | (m) | (m) |
| 2022-03-31 | $-44.19M | (m) | (m) | $34.50M | (m) | (m) |
| 2021-12-31 | $-32.93M | (m) | (m) | $26.24M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-4.84M | (m) | (m) | $3.04M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |